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doi:10.1016/j.pedneo.2011.08.005Background: Asthma is a chronic inflammatory disease of the airways for which current treat-
ments are mainly based on pharmacological interventions, such as glucocorticoid therapy. Our
objective was to study the immunoregulatory effects of caffeic acid phenethyl ester (CAPE,
a phytochemical synthesized from propolis) on cytokine secretion of peripheral blood mononu-
clear cells (PBMCs) from asthmatic children.
Methods: PBMCs from asthmatic children (5.5 3.3 years old, nZ 28) and healthy children
(5.6 2.8 years old, nZ 23) were co-cultured with CAPE in vitro with and without phorbol-
12-myristate-13-acetate-ionomycin.
Results: Our results show that predominant interleukin 4 (IL-4) and interferon-gamma secre-
tion of cultured supernatant were detected in healthy donors compared with asthmatics. In
the presence of phorbol-12-myristate-13-acetate-ionomycin, with or without CAPE treatment,
the asthmatic children showed significantly decreased levels of IL-10 secretion compared with
the healthy controls. However, CAPE significantly decreased IL-10 and interferon-gamma in
healthy donors. There was a slight but not statistically significant reduction of IL-4 secretion
in CAPE-treated PBMCs compared with untreated control PBMCs from the healthy children.
Our data also shows that CAPE significantly enhanced transforming growth factor-beta 1
production from PBMCs from asthmatic children.of Nutritional Science, Fu-Jen University, No. 510, Zhongzheng Road, Xinzhuang City, Taipei County
du.tw (W.-M. Wu).
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328 L.B. Sy et alConclusion: The immunoregulatory effects of CAPE on human PBMCs may be through the
induction of regulatory T cells, as evidenced by the enhanced transforming growth factor-beta
1 production from PBMCs from asthmatic children in our study.
Copyright ª 2011, Taiwan Pediatric Association. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
Caffeic acid phenethyl ester (CAPE) is a phytochemical
synthesized from honeybee propolis,1 a naturally occurring
bee product. Several studies have shown that CAPE has
antitumor,2e6 anti-inflammatory,7,8 and antioxidant prop-
erties.9e12 CAPE downregulates mitogen-induced T-cell
proliferation and lymphokine production13 by inhibition of
DNA binding and transcription of nuclear factor-kappa B
and the nuclear factor of activated T cells in stimulated T-
cells.14 In vivo, the immunomodulatory effects of CAPE
have also been observed in CAPE-administered mice, with
increased CD4þ T cell subsets and enhanced anti-CD3-
induced cytokine production in splenocytes.15 However,
there are no studies to date on how CAPE might affect the
immune response in asthma.
Asthma is a chronic inflammatory disease of the airways
caused by aberrant T-helper 2 (TH2) immune responses.
Activation of TH2 cells mediate the synthesis of immuno-
globulin E via interleukin-4 (IL-4) and eosinophilic inflam-
mation via IL-5, which, together with IL-13, contributes to
airway hyper-responsiveness and other clinical features of
allergic disease.16 Current pharmacotherapy for asthma
includes glucocorticoids for relief of wheezing in preschool
children.17 Although glucocorticoids can effectively control
attacks of asthma, many patients develop side effects as
a result of long-term steroid therapy.18 Even inhaled
glucocorticoids have been shown to suppress bone growth
in pediatric patients.19 Thus, there is a need for novel
therapeutic strategies, which are equally effective but with
minimal side effects. This study investigated the immuno-
regulatory effects of CAPE in vitro on cytokine secretion of
the peripheral blood mononuclear cells (PBMCs) isolated
from both asthmatic and healthy children.
2. Materials and Methods
2.1. Participants
Heparinized blood was obtained from 28 untreated asth-
matic patients (11 girls and 17 boys) and 23 healthy
nonallergic controls (9 girls and 14 boys). Average age was
5.5 3.3 years for asthmatic patients and 5.6 2.8 years
for healthy controls. Our asthmatic patients, children with
mild intermittent asthma who were not yet treated with
corticosteroids and/or bronchodilators, were recruited
from the Department of Pediatrics, Cardinal Tien Hospital
(Taipei, Taiwan). Healthy children, defined as those
without symptoms of allergic or infectious diseases, were
enlisted from participants at a promotional program hosted
by Cardinal Tien Hospital on December 18, 2004. Totalserum immunoglobulin E concentrations (analyzed by
chemiluminescence method) in asthmatic and healthy
children were 659.6 648.2 kU/L and 32.0 22.8 kU/L,
respectively. The study protocol was reviewed and
approved by the Committee on Human Experiments of
Catholic Cardinal Tien Hospital, Taipei, Taiwan. Written
informed consent was obtained from each participant’s
parents.
2.2. Reagents
CAPE was purchased from Sigma-Aldrich Chemical Co. (St
Louis, MO, USA). Phorbol 12-myristate 13-acetate (PMA)-
ionomycin was all purchased from Sigma (Germany).
2.3. Preparation of PBMCs
Human PBMCs were isolated from heparinized blood after
centrifugation in Ficoll-Hypaque (Pharmacia, Sweden)
density gradient. The PBMC layers were collected and
washed twice with cold Hanks’ buffer saline solution
(HyClone, USA). The cells were then resuspended in
complete medium (Roswell Park Memorial Institute 1640
media supplemented with 10% fetal bovine serum, 2mM L-
glutamine, 10mM HEPES, 100 U/mL penicillin, 100 U/mL
streptomycin, and 5.78 105M b-mercaptoethanol, all
purchased from HyClone, USA).
2.4. Quantification of cytokine secretion
by enzyme-linked immunosorbent assay
PBMC (2 106 cells/mL) were stimulated with 20 ng/mL
PMA, Sigma (Germany) and 1mM ionomycin (Sigma, Ger-
many) in the presence or absence of 2.5 mg/mL CAPE, and
supernatants were collected after 24 hours. Culture
supernatants were spun free of cells and aliquots were
frozen at 80C. Levels of transforming growth factor beta
1 (TGF-b1) in acidified supernatants were determined by
capture enzyme-linked immunosorbent assay according to
manufacturer’s instructions (R&D Systems, Germany).
Levels of IL-4, IL-5, IL-10, and interferon-gamma (IFN-g)
were measured by capture ELISA (BD PharMingen, USA)
according to manufacturer’s instructions.
2.5. Statistical analysis
Two-way analysis of variance was used to test for statis-
tically significant differences; p values less than 0.05 were
considered significant. All cultures were done in tripli-
cate, and standard deviations are represented by error
bars.
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To assess the effect of CAPE on TH1/TH2 cytokine secretion
in both healthy and asthmatic children, PBMCs were stim-
ulated using PMA-ionomycin in the presence or absence of
CAPE. As shown in Table 1, the levels of IL-4 secretion in the
untreated healthy controls were significantly higher
compared with the levels observed in the asthmatic chil-
dren. By contrast, PBMC production of IL-10 in untreated
asthmatics was found to be significantly higher than in the
healthy children (Table 1).
When PBMCs were stimulated with PMA-ionomycin, both
IL-4 and IFN-g secretion in asthmatics were lower than
those in healthy children, and a significant lowering of IFN-
g production was observed in the group of asthmatics
compared with that seen in healthy participants
(2.6 0.5 ng/mL vs. 49.4 16.1 ng/mL) (Table 2). CAPE
inhibited both IL-10 and IFN-g production in PMA-
ionomycin-stimulated PBMCs taken from healthy children.
There was a slight reduction of IL-4 secretion in CAPE-
treated PBMCs compared with the nontreated (control)
group in healthy children, but this difference did not reach
significance. Interestingly, CAPE reduced the production of
IFN-g and significantly enhanced the TGF-b1 in the asth-
matic PBMC culture supernatants. We also checked the
effects of CAPE on Th1/Th2 ratio of PMA-ionomycin-
activated PBMC isolated from asthmatic patients or
healthy donors. Figure 1 demonstrates that the presence of
CAPE did not change the trends of Th1/Th2 in both asth-
matic patients and healthy donors.
4. Discussion
Several studies have demonstrated the immunomodulatory
effects of CAPE. Cytokines such as IL-2, IL-4, and IFN-g
were significantly increased in BALB/c mice treated with












* Peripheral blood mononuclear cells from asthmatic patients or h
alone. Cultured supernatants from all treatment groups were collecte
linked immunosorbent assay.
y Values (mean standard deviation) with different superscript lette
two-way analysis of variance.
z Patient number: IL-4, asthmatics: 11, healthy: 12; IL-5, asthmatic
matics: 11, healthy: 12; TGF-b1, asthmatics: 11, healthy: 12.
CAPEZ caffeic acid phenethyl ester; IFN-gZ interferon-g gamma; ILtreated with CAPE shifted from an irradiation-induced Th2-
like pattern of gene expression toward Th1 gene expression
by an apoptotic sensitization pathway. It has been recently
shown that CAPE suppresses phytohemagglutinin-induced
cytokine production of PBMCs taken from healthy adult
volunteers.13 Thus, we studied the effects and mechanisms
of CAPE on Th1/Th2 cytokines regulation of PBMC isolated
from asthmatic and healthy children. Our study showed
that spontaneous IL-4 secretion was higher in healthy
children in contrast to significantly higher production of IL-
10 in asthmatic children (Table 1). There was a slight
reduction of IL-4 secretion in CAPE-treated PBMCs
compared with the nontreated (control) group in healthy
children, but this difference did not reach statistically
significant result. But when PBMCs were stimulated with
PMA-ionomycin, both IL-4 and IFN-g secretion in asthmatics
were lower than those in healthy children, and a signifi-
cantly lowered IFN-g production was observed in the group
of asthmatic compared with that seen in healthy partici-
pants (Table 2). We surmise that these asthmatic patients
(before treatment with glucocorticoids or bronchodilators)
had ongoing acute attacks of asthma when they were
included in this study, and PBMCs taken during this time
failed to show any further increase of cytokine secretion
with PMA stimulation as compared with baseline levels as
noted by Kuo et al.21 The lower IFN-g production observed
in the group of asthmatics compared with that seen in
healthy participants is explained by the fact that IFN-g is
primarily produced by Th1 cells22 and asthma is caused by
aberrant Th2 immune responses. CAPE inhibited both IL-10
and IFN-g production in PMA-ionomycin-stimulated PBMC
separated from healthy children. It can be seen that CAPE
suppresses spontaneous and PMA-ionomycin-induced cyto-
kine production of PBMCs isolated from both healthy and
asthmatic children.
As already suggested in previous studies, CAPE inhibits
phytohemagglutinin-stimulated cytokine production of, but
induces TGF-b1 production in healthy adult PBMCs.13 Ourod mononuclear cells from asthmatic and healthy children.*
,y
Healthyz Asthmaticz
37.0 38.7X 0.0 0.0Y
26.6 39.7 4.4 14.6
1.9 3.2 5.9 7.7
0.0 0.2 1.5 4.6
350.5 249.0X 1283.5 597.3Y
255.9 236.5X 1029.6 606.0Y
56.3 87.0 30.7 49.2
18.3 36.4 13.7 12.0
4.2 2.3 2.8 1.4
3.5 2.3 3.3 1.3
ealthy donors were cultured with CAPE (2.5 mg/mL) or medium
d following 24 hours of incubation and then analyzed by enzyme-
rs in the same row (X, Y) were significantly different (p< 0.05) via
s: 10, healthy: 12; IL-10, asthmatics: 8, healthy: 9; IFN-g, asth-
Z interleukin; TGF-b1Z transforming growth factor beta 1.
Table 2 Effects of CAPE on cytokines secretions by phorbol-12-myristate-13-acetate-ionomycin-activated peripheral blood
mononuclear cells.*,y
Cytokine Treatment Healthyz Asthmaticz
IL-4 (pg/mL) Control 183.8 137.2X 76.6 36.2Y
CAPE 2.5 mg/mL 126.3 68.9X 65.3 22.7Y
IL-5 (pg/mL) Control 568.4 321.0 522.2 260.4
CAPE 2.5 mg/mL 459.5 248.1 459.4 400.7
IL-10 (pg/mL) Control 591.9 217.3A,X 229.5 236.4Y
CAPE 2.5 mg/mL 288.7 145.2B,X 91.1 94.9Y
IFN-g (ng/mL) Control 49.2 16.1A,X 2.6 0.5A,Y
CAPE 2.5 mg/mL 28.7 10.4B,X 2.2 0.6B,Y
TGF-b1 (ng/mL) Control 5.9 3.3 4.1 1.9B
CAPE 2.5 mg/mL 6.3 4.0 6.0 2.1A
* Peripheral blood mononuclear cells from asthmatic patients or healthy donors were cultured with CAPE (2.5 mg/mL) or medium
alone. Cultured supernatants from all treatment groups were collected following 24 hours of incubation and then analyzed by enzyme-
linked immunosorbent assay.
y Values (mean  SD) with different superscript letters in the same column (A, B) or between asthmatics and healthy participants (X, Y)
were significantly different (p< 0.05) via two-way analysis of variance.
z Patient number: IL-4, asthmatics: 11, healthy: 12; IL-5, asthmatics: 10, healthy: 12; IL-10, asthmatics: 8, healthy: 9; IFN-g, asth-
matics: 11, healthy: 12; TGF-b1, asthmatics: 11, healthy: 12.
CAPEZ caffeic acid phenethyl ester; IFN-gZ interferon-g gamma; ILZ interleukin; TGF-b1Z transforming growth factor beta 1.
330 L.B. Sy et alstudy showed that CAPE reduced the production of IFN-g
and significantly enhanced the TGF-b1 in the asthmatic
PBMC culture supernatants (Table 2). Moreover, CAPE
inhibits cytokine synthesis in stimulated T-cells, a result
that correlated with its ability to inhibit PMA-ionomycin-
induced DNA binding and transcriptional activity of
nuclear factor of activated T cells.14 Our study demon-
strated that the possible immunoregulatory effect of CAPE
is to induce the expression of regulatory T (Treg)-like cells
in activated PBMC from asthmatic and healthy participants,Figure 1 Effects of CAPE on Th1/Th2 ratio of phorbol-12-
myristate-13-acetate (PMA)-ionomycin-activated peripheral
blood mononuclear cells (PBMCs) isolated from asthmatic
patients or healthy donors.1,2 PBMCs were isolated from asth-
matic patients (nZ 11) or healthy donors (nZ 12) and stimu-
lated with PMA plus ionomycin in the presence or absence of
CAPE. After 24 hours of incubation, cultured supernatants were
collected and analyzed by enzyme-linked immunosorbent
assay. The Th1/Th2 ratio was calculated as the ratio of
interferon-gamma and interleukin-4. *A p value < 0.001 for
comparison between asthmatic group and healthy group.
CAPEZ caffeic acid phenethyl ester.which can promote TGF-b secretions from T cells and
further inhibit Th1/Th2 cytokine secretions (Figure 1).
Recently, Treg cells have emerged as master regulators
of immunity and a new target for asthmatic intervention.
Several types of Treg cells exist, including CD4þ T-cells that
express CD25þ constitutively (CD4þ CD25þ cells). Regula-
tory T-cells suppress immune responses via direct cell-to-
cell interactions, and Type 1 T regulatory cells function
via secretion of IL-10 and TGF-b1 cells.23 When activated,
Treg cells produce IL-10, TGF-b1, and lower levels of IFN-g,
but do not affect levels of IL-2 or IL-4, a profile of cytokine
production, which is remarkably similar to that of Type 1 T-
regulatory cells.24
There is evidence that the function of Treg cells appears
to be compromised in those with allergic diseases, including
rhinitis, atopic dermatitis, and asthma.25 The exact mecha-
nisms of suppression used by Treg cells remain controversial.
Our study shows that in the presence of PMA-ionomycin,
asthmatic children had significantly lower levels of IL-10
secretions than healthy children, which might suggest
a compromised function in Treg cells in allergic diseases. Our
results also shows CAPE significantly upregulated levels of
TGF-b1 levels, which is also a marker of Treg cells. The
immunoregulatory effects of CAPE on human PBMC may be
through the induction of Treg-like cells as evidenced by the
enhanced TGF-b1 production in PBMCs from asthmatic chil-
dren in our study.
The conclusion of our in vitro study is that CAPE could
increase TGF-b1 secretion by PBMCs of asthmatic children,
and CAPE could inhibit IL-10 secretion, too. Although the
PMA-ionomycin-stimulated PBMCs treated with CAPE could
attenuate IFN-g secretion, the ratios of Th1 and Th2 cyto-
kines were not changed as compared with PBMCs stimu-
lated with or without CAPE. To verify the therapeutic effect
of CAPE in asthma, an in vivo study of the effect of CAPE on
animal model of airway inflammation will be needed in the
future.
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